Plasma Melatonin AND Mortality After Acute Myocardial Infarction

Early-morning Plasma Melatonin Levels Predict Cardiovascular Mortality After Acute Myocardial Infarction

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03230630

Enrollment

732

Registered

2017-07-26

Start date

2013-01-01

Completion date

2017-01-01

Last updated

2017-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melatonin, Myocardial Infarction

Brief summary

Pre-clinical and clinical studies have demonstrated that melatonin has cardio-protection effects. Melatonin has anti-inflammatory, antioxidant, antihypertensive, antithrombotic and antilipaemic properties, which plays important roles in a variety of cardiovascular pathophysiologic processes. Nocturnal melatonin levels decreased after AMI, and lower serum melatonin concentrations after AMI are associated with more heart failure and cardiac death and left ventricular remodeling. Moreover in women with increased BMI, lower melatonin secretion is associated with higher risks of MI. Early-morning blood collection is easier in clinical practice. Therefore, the investigators carried out a cohort study to evaluate the prognostic value of plasma soluble melatonin in hospitalized patients with acute myocardial infarction (AMI).

Interventions

DIAGNOSTIC_TESTplasma melatonin levels

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* consecutive patients of acute AMI come to department of cardiology, 301 hospital (Beijing, China),absent of cardiogenic shock, and survival for at least 24 h after percutaneous coronary intervention treatment.

Exclusion criteria

* patients with autoimmune diseases, collagen tissue diseases, drug addiction, radiotherapy, patients receiving immunosuppressive treatment, taking sedatives, antiepileptic drugs, tricyclic antidepressants or any medication known to influence melatonin metabolism, psychiatric sleeping disorders, shift workers, and subjects with jet-lag syndrome

Design outcomes

Primary

Measure	Time frame
cardiovascular mortality	The median follow-up was 31.6 months

Secondary

Measure	Time frame	Description
non-cardiovascular mortality	The median follow-up was 31.6 months	—
Myocardial infarction	The median follow-up was 31.6 months	—
heart failure readmission	The median follow-up was 31.6 months	readmission to any hospital due to diagnosed heart failure
Stroke	The median follow-up was 31.6 months	defined using the World Health Organization criteria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026